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Abstract
Background: Undernourished, HIV-infected adults in sub-Saharan Africa have high levels of systemic inflammation,
which is a risk factor for mortality and other adverse health outcomes. We hypothesized that microbial translocation,
due to the deleterious effects of HIV and poor nutrition on intestinal defenses and mucosal integrity, contributes to
heightened systemic inflammation in this population, and reductions in inflammation on antiretroviral therapy (ART)
accompany reductions in translocation.
Methods: HIV-infected, Zambian adults with a body mass index <18.5 kg/m2 were recruited for a pilot study to
assess the relationships between microbial translocation and systemic inflammation over the first 12 weeks of ART.
To assess microbial translocation we measured serum lipopolysaccharide binding protein (LBP), endotoxin core IgG
and IgM, and soluble CD14, and to assess intestinal permeability we measured the urinary excretion of an oral
lactulose dose normalized to urinary creatinine (Lac/Cr ratio). Linear mixed models were used to assess within-patient
changes in these markers relative to serum C-reactive protein (CRP), tumor necrosis factor-α receptor 1 (TNF-α R1), and
soluble CD163 over 12 weeks, in addition to relationships between variables independent of time point and adjusted
for age, sex, and CD4+ count.
Results: Thirty-three participants had data from recruitment and at 12 weeks: 55% were male, median age was
36 years, and median baseline CD4+ count was 224 cells/μl. Over the first 12 weeks of ART, there were significant
decreases in serum levels of LBP (median change -8.7 μg/ml, p = 0.01), TNF-α receptor 1 (-0.31 ng/ml, p < 0.01), and
CRP (-3.5 mg/l, p = 0.02). The change in soluble CD14 level over 12 weeks was positively associated with the change in
CRP (p < 0.01) and soluble CD163 (p < 0.01). Pooling data at baseline and 12 weeks, serum LBP was positively
associated with CRP (p = 0.01), while endotoxin core IgM was inversely associated with CRP (p = 0.01) and TNF-α
receptor 1 (p = 0.04). The Lac/Cr ratio was not associated with any serum biomarkers.
Conclusions: In undernourished HIV-infected adults in Zambia, biomarkers of increased microbial translocation
are associated with high levels of systemic inflammation before and after initiation of ART, suggesting that
impaired gut immune defenses contribute to innate immune activation in this population.
Keywords: HIV infection, Antiretroviral therapy, Microbial translocation, Nutrition, Sub-Saharan Africa, Inflammation
* Correspondence: john.r.koethe@vanderbilt.edu
5Vanderbilt Institute for Global Health, Nashville, TN, USA
8Division of Infectious Diseases, Department of Medicine, Vanderbilt
University School of Medicine, A2200-MCN, 1161 21st Avenue South,
Nashville, TN, USA
Full list of author information is available at the end of the article
© 2014 Canipe et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Canipe et al. BMC Infectious Diseases 2014, 14:521
http://www.biomedcentral.com/1471-2334/14/521
Background
The epidemics of human immunodeficiency virus (HIV),
chronic undernutrition, and food insecurity dispropor-
tionately affect Sub-Saharan Africa, and nutritional deficits
contribute to increased morbidity and mortality among
HIV-infected individuals in the region [1]. Undernour-
ished (defined as body mass index [BMI] < 18.5 kg/m2)
HIV-infected adults have a strikingly high early mortality
rate after initiation of antiretroviral therapy (ART), over
25% in the first 90–180 days in some studies, which is
4–6 fold higher than HIV-infected patients who are ad-
equately nourished and is independent of the degree of
immunosuppression (CD4+ T-cell count) [2-5]. The
mechanism underlying this high early mortality is un-
known and likely multifactorial, but prior studies have
found heightened systemic inflammation to be a major
risk factor [6,7].
In studies of predominantly well-nourished individ-
uals, microbial translocation has been proposed as an
etiology of the persistent immune activation observed in
patients with both untreated and treated HIV. However,
there are few reports on the contribution of microbial
translocation to the exceptionally high levels of systemic
inflammation observed in patients with comorbid mal-
nutrition and advanced HIV disease in resource-limited
settings [8-10].
HIV infection depletes CD4+ cells in the gastrointes-
tinal mucosa, particularly Th17 regulatory T-cells inte-
gral to defense against bacterial, fungal, and parasitic
pathogens, and impairs tight junctions between epithelial
cells, resulting in altered intestinal integrity and in-
creased translocation of microbes from the intestinal
lumen to the circulation [11-15]. Increased microbial
translocation, as measured by circulating lipopolysac-
charide (LPS; a component of the bacterial cell wall),
anti-endotoxin antibodies, soluble CD14 (sCD14), and
other biomarkers is associated with accelerated HIV dis-
ease progression and a higher risk of mortality [16,17].
Irrespective of HIV infection status, chronic undernutri-
tion also impairs intestinal mucosal integrity and permits
increased microbial translocation in a manner similar to
advanced HIV infection, suggesting that the presence of
both conditions in the same host may have compound-
ing effects [18,19].
We hypothesized that the high levels of systemic in-
flammation observed in undernourished adults with ad-
vanced HIV in sub-Saharan Africa are due in part to
excessive microbial translocation, and reductions in mi-
crobial translocation following treatment initiation ac-
company a normalization of this inflammatory response.
To test this hypothesis, we conducted a pilot study to
measure intestinal permeability, microbial translocation,
and systemic inflammation among undernourished,
HIV-infected African adults starting ART.
Methods
This study was nested within a prospective, randomized-
controlled trial of nutritional support to reduce early ART
mortality (the Nutritional Support for African Adults
Starting Antiretroviral Therapy [NUSTART] study –
trial registration #PACTR201106000300631). Briefly,
the NUSTART study was a randomized controlled trial
of a lipid-based nutritional supplement, with or without
additional vitamins and minerals, conducted in Zambia
and Tanzania between 2011 and 2013 among HIV-
infected, ART-eligible adults with clinical malnutrition
(defined as a BMI < 18.5 kg/m2) [20]. We enrolled a
subset of trial participants from Zambia into a prospective
cohort to evaluate markers of intestinal permeability, mi-
crobial translocation, and systemic inflammation from re-
cruitment through the first 12 weeks of ART (inclusive of
nutritional supplementation from enrollment to 6 weeks
after starting ART).
Potentially eligible participants were evaluated by
study staff at local health clinics and referred to Univer-
sity Teaching Hospital in Lusaka, Zambia for enrollment
in the parent NUSTART trial and all study procedures.
Inclusion criteria were at least 18 years of age, ART-
naïve (except for prior receipt of Prevention of Mother
To Child Transmission regimens), ART-eligibility as de-
termined by CD4+ T-cell count <350 cells/μl, BMI <
18.5 kg/m2, willingness to undertake intensive ART
follow-up in the study clinic, and not pregnant.
Enrollment for this sub-study occurred from August
2012 through December 2012. Prior to starting ART and
after 12 weeks of treatment, microbial translocation
across the gut wall was assessed by measuring serum
levels of LPS binding protein (LBP), endotoxin core IgG
(EndoCAb IgG) and EndoCAb IgM (two antibodies pre-
viously shown to rise and fall, respectively, in response
to circulating LPS levels) [21], and sCD14 using ELISA
(Hycult Biotech, Uden, Netherlands). To assess systemic
inflammation we measured serum levels of C-reactive
protein (CRP), soluble TNF-α receptor 1, and soluble
CD163 (sCD163, a marker of monocyte activation) using
ELISA (R&D Systems, Minneapolis, MN USA). Intes-
tinal permeability was measured using the fractional ab-
sorption and urinary excretion of lactulose method (Lac/
Cr ratio). Patients ingested a 10 g dose of lactulose pow-
der (Kristalose, Cumberland Pharmaceuticals, Nashville,
TN, USA) dissolved in water, and urine was collected
over a 5 hour period. The urine concentration of lactulose
in mmol/l was measured using an enzymatic, spectro-
photometric technique and normalized to urine creatinine
in mol/l (Oxford Biomedical Research, Rochester Hills,
MI, USA) [22,23]. Participants who reported more than
four bowel movements in the 24 hours preceding the en-
rollment were excluded from the lactulose urinary excre-
tion testing because lactulose is a cathartic agent which
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could exacerbate diarrhea and contribute to volume
depletion.
Participant clinical and demographic characteristics
were expressed as percentages or as median values with
interquartile range. The change in each biomarker from
recruitment to 12 weeks of ART was assessed using the
Wilcoxon signed rank test. Local polynomial regression
fitting (loess) curves were fit to provide smoothed
trends. We assessed the relationships between perme-
ability, microbial translocation and inflammation bio-
markers irrespective of time point (baseline or 12 weeks)
using a linear mixed model with a random effect for the
patient to account for correlation that may arise from
measurements taken from the same patient, and ad-
justed for age, sex, and pre-treatment CD4+ T-cell
count. The permeability and translocation biomarkers
(LBP, EndoCAb IgG and IgM, sCD14, and urinary Lac/
Cr ratio) were log-transformed whereas inflammation
biomarkers (CRP, TNF-α R1, and sCD163) remained on
the unit scale. The primary analysis included the 33 par-
ticipants evaluated at both recruitment and 12 weeks; a
secondary analysis incorporated the recruitment visit
data from 27 additional patients without 12 week data.
Lastly, we assessed the relationship between the change
in permeability and translocation biomarkers with the
change in inflammation over the 12 weeks (i.e., within-
patient comparison) using ordinary least squares regres-
sion, with adjustment for the baseline biomarker values
so that the effect measure is independent of baseline.
Analyses were performed using R (version 2.12.1;
www.r-project.org). Analysis scripts are posted at http://
biostat.mc.vanderbilt.edu/wiki/Main/ArchivedAnalyses.
The study was approved by the Institutional Review
Board at Vanderbilt University and the Biomedical Re-
search Ethics Committee of the University Teaching
Hospital in Lusaka, Zambia, and all patients provided
written informed consent.
Results
Sixty ART-naïve adults were recruited for this study be-
tween August and December 2012, and 33 returned at
12 weeks for the clinical assessment and laboratory stud-
ies. Of the 27 patients without week 12 data, one-third
(n = 9) had never started ART, 2 died, 3 withdrew due to
relocation, pregnancy, or acute illness, and 13 declined
to return for week-12 measurements. Those included
and excluded from the analysis did not differ according
to age, sex, or pre-treatment BMI, serum hemoglobin, or
CD4+ T-cell count (p > 0.05 for all). Among the 33 pa-
tients included in the follow-up analysis, 55% were
male and at enrollment, the median age was 36 years
(interquartile range [IQR] 31–42), and the median CD4+
T-cell count was 224 cells/μl (IQR 151–256); all partici-
pants were undernourished according to WHO criteria
(i.e. BMI <18.5 kg/m2), with a median BMI of 16.7 kg/m2
(IQR 15.4-17.6). Table 1 shows the clinical characteristics
of the 33 included cohort patients. Ten of the participants
had fewer than 4 pairs of laboratory data and could not be
included in some of the statistical models. Compared to
the other 23 patients, those with fewer than 4 data pairs
were similar by age, sex, hemoglobin or CD4+ T-cell
count (p > 0.05 for all), but had lower pre-treatment BMI
(15.6 versus 17.4 kg/m2; p = 0.02).
Participants reported a range of clinical complaints at
enrollment including cough (66%), subjective fever (41%),
pain with swallowing (13%), abdominal pain (44%), diar-
rhea (28%), shortness of breath (25%), and vomiting (9%),
but there were no significant differences in any of the
baseline microbial translocation or inflammation bio-
marker levels between participants with and without these
complaints (data not shown). Similarly, there were no sig-
nificant differences in biomarker levels between those on
therapy for tuberculosis (22%) or with recent diarrheal ill-
ness (4%) at enrollment.
From recruitment to 12 weeks of ART there was a
significant decrease in serum levels of LBP (median
change -8.7 μg/ml, p = 0.01), TNF-α receptor 1 (-0.31 ng/ml,
p < 0.01), and CRP (-3.5 mg/l, p = 0.02). An increase in
Table 1 Description of the cohort (n = 33)
Demographic and clinical characteristics
Female sex, n (%) 15 (45%)
Age (median years, IQR) 36 (31–42)
Baseline BMI
(median kg/m2, IQR)
16.7 (15.4 - 17.6)
Week 12 BMI
(median kg/m2, IQR)
17.6 (16.5 - 19.0)*
Baseline CD4+ count
(median cells/μL, IQR)
224 (151–256)
Week 12 CD4+ count
(median cells/μL, IQR)
349 (275–426)*
Median serum and urine biomarker values pre-treatment
and after 12 weeks of antiretroviral therapy, median (IQR)
Biomarker Recruitment Week 12 of ART
Lipopolysaccharide binding
protein (μg/ml)
46.7 (33.6 – 74.3) 38.4 (31.1 – 44.4)*
Soluble CD14 (μg/ml) 2.4 (2.0 - 2.6) 2.5 (2.0 - 3.1)
Endotoxin core IgM (units/ml) 14.1 (12.7 - 20.0) 17.7 (11.7 - 22.7)
Endotoxin core IgG (units/ml) 38.4 (23.9 - 86.6) 32.9 (16.1 - 94.5)
C-reactive protein (mg/l) 18.3 (4.5 - 64.8) 6.4 (3.8 - 19.7)*
TNF-α receptor 1 (ng/ml) 1.3 (0.8 – 2.4) 1.0 (0.6 – 1.3)*
Soluble CD163 (ng/ml) 684 (511–1022) 531 (376–1040)
Urine lactulose-to-creatinine
ratio (mmol/mol)
29.3 (12.6 – 55.2) 34.0 (14.1 – 86.3)
Abbreviation: ART antiretroviral therapy, BMI body mass index, TNF-α tumor
necrosis factor-α, IQR interquartile range.
*p < 0.05 for change at 12 weeks.
Canipe et al. BMC Infectious Diseases 2014, 14:521 Page 3 of 9
http://www.biomedcentral.com/1471-2334/14/521
EndoCAb IgM antibody (0.6 units/ml, p = 0.11) did not
reach statistical significance. The Figure 1 shows the
changes in the biomarkers from recruitment to
12 weeks of ART among all patients with paired sam-
ples, with smoothed curves fit to demonstrate overall
trends, while the Additional file 1: Figure S1 shows the
changes for inflammatory biomarkers as a function of
changes in microbial translocation biomarkers.
Associations between pooled baseline and 12-week
biomarkers of intestinal permeability, microbial trans-
location and inflammation were assessed using linear
mixed models adjusted for age, sex, and baseline CD4+
T-cell count (Table 2). Serum LBP level was positively
associated with CRP (p = 0.01), and closely related to
TNF-α receptor 1 and sCD163 (p = 0.08 and p = 0.13, re-
spectively). Serum EndoCAb IgM level (a circulating
antibody shown in prior studies to rise in response to
decreasing microbial translocation) was inversely associ-
ated with serum levels of CRP (p = 0.01) and TNF-α re-
ceptor 1 (p = 0.04) [21]. Serum sCD14 was associated
with CRP (p < 0.01) and sCD163 (p < 0.01), and closely
related to TNF-α receptor 1 (p = 0.07). We did not de-
tect statistically significant relationships between Endo-
CAb IgG or the urine Lac/Cr ratio and the inflammatory
biomarkers. Results were similar when recruitment data
from participants without a week 12 visit were included
in the analysis.
In the linear models, the change in sCD14 from recruit-
ment to 12 weeks was associated with the change in CRP
(p = 0.02) and sCD163 (p = 0.01) (Table 3). However, the
change in EndoCAb IgM at 12 weeks was also positively
associated with the change in sCD163 (p = 0.02), which
was unexpected given the results from the pooled ana-
lyses. Changes in other translocation biomarkers over
12 weeks were not significantly associated with changes in
inflammation.
Lastly, we assessed the relationship between the urin-
ary Lac/Cr ratio, our biomarker of intestinal permeabil-
ity, and the microbial translocation and inflammation
biomarkers. We failed to detect any association of Lac/
Cr ratio with serum levels of LBP, EndoCAb IgM, Endo-
CAb IgG, or sCD14 in the linear mixed models, nor was
the change in Lac/Cr over 12 weeks associated with the
change in any of the translocation biomarkers over the
same period. Similarly, the Lac/Cr ratio was not associ-
ated with the measures of systemic inflammation.
Discussion
In this pilot study of undernourished adults starting
ART in sub-Saharan Africa, serum levels of circulating
CRP and other inflammatory biomarkers were markedly
elevated prior to treatment initiation and after 12 weeks,
and there was evidence that reductions in microbial
translocation biomarkers, particularly LBP, accompanied
reductions in inflammatory biomarkers. However, while
we observed close associations between several pairs of
translocation and inflammation biomarkers, there was
marked heterogeneity both between and within partici-
pants. This suggests the hypothesis that microbial
translocation is a primary driver of inflammation in
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Figure 1 Changes in microbial translocation and inflammation biomarkers after 12 weeks of antiretroviral therapy. Yellow lines
represent paired samples and the blue lines represent loess curves. As in the statistical models, the permeability and translocation biomarkers are
log-transformed (with the y-axis labeled in the original scale) and the inflammation biomarkers are on the unit scale. Wilcoxon signed rank test
assessed statistical significance.
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HIV-infected adults does not adequately capture what
is likely a complex interplay of factors promoting innate
immune activation in malnourished adults with ad-
vanced HIV disease.
Microbial translocation in undernourished, HIV-infected
adults is likely due to the combined effects of HIV enterop-
athy, environmental enteropathy, and malnutrition on the
intestinal mucosal barrier. HIV enteropathy generally oc-
curs in advanced disease (e.g., CD4+ T-cell count <200
cells/μl) and is characterized by changes in villous mor-
phology, absorption, and mucosal permeability [24,25].
Mucosal T-cell depletion, particularly loss of the Th17 cells
important for bacterial, fungal, and parasitic defense, in
conjunction with impaired cellular tight junctions has been
proposed as an underlying mechanism [13,14,26]. Environ-
mental enteropathy is common in many tropical re-
gions, including Zambia, and is morphologically similar
to HIV enteropathy [27]. It is thought to result from a
combination of recurrent, transient infections with
pathogenic bacteria and altered intestinal microbiota
resulting in chronic T-cell mediated enteric inflamma-
tion, malabsorption, impairment of mucosal integrity,
Table 2 Regression coefficients estimating the associations between biomarkers of microbial translocation and
inflammation
Inflammation biomarkers
Microbial translocation biomarkers C-reactive protein Soluble CD163 TNF-α receptor 1
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
p-value; model size p-value; model size p-value; model size
Lipopolysaccharide binding protein 28.9 (8.6, 49.1) 169 (−14, 352) 773 (−11, 1559)
p = 0.01; n = 40 p = 0.13; n = 40 p = 0.08; n = 40
Endotoxin core IgM antibody −25.7 (−42.7, −8.7) −4.4 (−164, 155) −713 (−1439, 12)
p = 0.01; n = 38 p = 0.90; n = 38 p = 0.04; n = 40
Endotoxin core IgG antibody −4.9 (−17.1, 7.4) 39 (−58, 137) −324 (−762, 113)
p = 0.58; n = 36 p = 0.76; n = 36 p = 0.54; n = 38
Soluble CD14 44.7 (21.3, 68.2) 595 (289, 902) 620 (8, 1232)
p < 0.01; n = 40 p < 0.01; n = 62 p = 0.07; n = 62
Urine lactulose/creatinine ratio (linear) 0.22 (−0.02, 0.45) 11 (−118, 140) 141 (−186, 468)
p = 0.33; n = 27 p = 0.68; n = 38 p = 0.81; n = 39
Results from linear mixed models pooling data across both recruitment and 12 weeks of ART. Models adjusted for age, sex, and baseline CD4+ T-cell count.
Microbial translocation biomarkers (regression predictor) are log-transformed and inflammation biomarkers (regression outcome) remain on the unit scale.
Model size represents total observations (recruitment and 12 week). Bold values represent statistically significant findings.
Table 3 Paired changes in microbial translocation and inflammation biomarkers over 12 weeks of ART
Inflammation biomarkers (12 week change)
Microbial biomarkers (12 week change) C-reactive protein Soluble CD163 TNF-α receptor 1
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
p-value; model size p-value; model size p-value; model size
Lipopolysaccharide binding protein −19 (−72, 33) 13 (−510, 536) 757 (−1256, 2769)
p = 0.45; n = 20 p = 0.96; n = 20 p = 0.44; n = 20
Endotoxin core IgM antibody −18 (−61, 25) 436 (72, 800) −74 (−1628, 1480)
p = 0.38; n = 19 p = 0.02; n = 19 p = 0.92; n = 30
Endotoxin core IgG antibody −1.2 (−34, 31) 168 (−86, 423) −500 (−1413, 412)
p = 0.94; n = 17 p = 0.18; n = 17 p = 0.26; n = 18
Soluble CD14 38 (7, 69) 697 (183, 1212) 553 (−208, 1313)
p = 0.02; n = 20 p = 0.01; n = 30 p = 0.15; n = 20
Urine lactulose/creatinine ratio (linear) −0.27 (−22, 21) 154 (−79, 388) 121 (−86, 329)
p = 0.97; n = 11 p = 0.17; n = 14 p = 0.22; n = 14
Linear models estimate the relationships between 12-week changes in the log-transformed microbial translocation biomarkers (regression predictor) and 12-week
changes in the inflammatory biomarkers (regression outcome) using ordinary least squares regression, adjusted for baseline biomarker values. Model size repre-
sents number of paired observations. Bold values represent statistically significant findings.
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and reduced expression of antimicrobial peptides [27-30].
Lastly, malnutrition is associated with hypoalbuminemia
and bowel wall edema, impaired adaptive immune re-
sponses, and reduced mucosal integrity [18,19,31].
Recent studies suggest that interventions to alter intes-
tinal microbiota and mucosal cellular function in comor-
bid malnutrition and advanced HIV disease could provide
clinical benefits for these patients, though much of this re-
search remains at an early stage. There is evidence to sug-
gest that probiotics can alter gastrointestinal tract
microbiota, with beneficial effects on mucosal immunity
[32]. In the HIV-infected population, administration of
probiotics and other specialized nutritional products has
led to modest improvements of CD4+ T-cell counts, re-
duced CD4+ T cell activation, and fewer gastrointestinal
disorders [33-36]. In the mouse model, glucagon-like pep-
tide and probiotics improved intestinal integrity and re-
duced inflammation in obese mice [37]. Other promising
non-human trials have demonstrated that vaccines may
improve gastrointestinal tract immunity by recruiting IgA
secreting plasma cells to the mucosa or decreasing the
local HIV burden [38,39], and the use of a bovine serum
immunoglobulin in adults with HIV enteropathy im-
proved duodenal absorptive function and increased muco-
sal CD4+ T cell density [40].
While increased microbial translocation and systemic
inflammation are both associated with poorer health
outcomes in HIV infection, further research is needed to
understand the clinical consequences in undernourished
African patients and to determine if prior findings in US
and European cohorts are applicable to this population.
In a US cohort of ART-treated adults, higher serum
levels of intestinal fatty acid binding protein and lower
zonulin-1, both indicative of increased gut permeability,
were associated with increased all-cause mortality [41].
In Italian HIV patients, serum LPS levels predicted dis-
ease progression independently of age, CD4+ T-cell
count, viral load, or duration of infection, and higher cir-
culating LPS levels after ART initiation were associated
with greater CD4+ and CD8+ T-cell activation and poor
CD4+ T-cell recovery [16,42]. Increased microbial trans-
location is also associated with dyslipidemia, insulin
resistance, and increased risk of cardiovascular events
in both HIV-infected and uninfected individuals
[43-45], and persistently elevated CRP and other
inflammation biomarkers predispose to fatal and non-
fatal cardiovascular events [46,47]. However, conclu-
sions regarding long-term health outcomes in African
populations based on these studies are not warranted
given differences in populations, background disease
risk, methodology, and other factors. Further epidemi-
ologic studies are needed to determine how very high
levels of both microbial translocation and inflamma-
tion affect risk for cardiovascular, metabolic and other
non-communicable diseases among HIV patients in
sub-Saharan Africa.
While sCD14 has been posited as a marker of micro-
bial translocation in prior studies of HIV-infected and
uninfected populations, the association between sCD14
and inflammatory markers observed in our study and
prior studies should be interpreted with caution
[8,9,16,48-50]. A major uncertainty is whether high cir-
culating sCD14 levels observed in HIV patients derive
from intestinal or hepatic immune cells (e.g., intestinal
monocytes or Kupffer cells exposed to LPS via the portal
vein) and thus reflect increased intestinal microbial tran-
sit, or whether the increased sCD14 derives from im-
mune cells in more distant tissues and should be
classified as a general biomarker of systemic inflamma-
tion [51]. This uncertainty reduces the utility of sCD14
as an indicator of microbial translocation.
Our measurements of Lac/Cr ratio were not associated
with any of our serum markers of microbial transloca-
tion, suggesting that intestinal permeability as measured
by this method may not represent the same epithelial
defects involved in increased microbial transit. In our
cohort, the median baseline Lac/Cr ratio value of
29.3 mmol/mol was approximately 3-fold higher than in
healthy controls in a prior study of European adults, but
considerably lower than patients with active Crohn’s dis-
ease [52]. Furthermore, we did not observe a clinically
significant change in the Lac/Cr ratio over 12 weeks,
which may indicate that while defenses against microbial
translocation improved on ART, paracellular absorption
from the gut lumen remained elevated. However, the use
of the Lac/Cr ratio in HIV-infected, malnourished adults
requires further validation given the chronic dehydration,
potential HIV- and nutrition-related renal dysfunction,
and reduced muscle mass present in this population.
Our pilot study was limited by small sample size and
incomplete follow-up of some participants. The lack of
both a non-malnourished, HIV-infected control group
and a malnourished, uninfected control group made it
impossible to explore the independent, and potentially
synergistic, contributions of HIV and malnutrition to mi-
crobial translocation. The inverse association we observed
between EndoCAb IgM and inflammation markers was
expected based on prior sepsis studies showing that Endo-
CAb IgM levels vary inversely with serum endotoxin in
the post-acute phase; however, we did not see any associ-
ation between EndoCAb IgG and the outcomes of interest
[21]. One possibility is that the EndoCAb IgG required ad-
justment for total IgG level, which is both high and vari-
able in HIV infection. Future studies would also benefit
from quantification of serum LPS or bacterial DNA and
analysis of intestinal histology, rather than the surrogate
markers of microbial translocation we used. Lastly, our
study did not measure plasma HIV-1 RNA levels, which
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may have had independent pro-inflammatory effects and
confounded our analysis, particularly if not all participants
reached viral suppression after 12 weeks of treatment.
Conclusions
Our findings suggest that excessive microbial transloca-
tion across the bowel wall contributes to the high levels
of systemic inflammation observed in undernourished
adults with advanced HIV disease in sub-Saharan Africa.
A high degree of translocation is likely due to the com-
pounding effects of HIV enteropathy, environmental en-
teropathy, and malnutrition on mucosal barrier integrity
and local immune defenses. Given the known adverse ef-
fects of heightened inflammation and microbial trans-
location on morbidity, mortality, and immune recovery
after ART initiation, the development of interventions to
improve gastrointestinal health in these patients may
have important benefits for clinical outcomes.
Additional file
Additional file 1: Figure S1. Directional change in inflammation and
microbial translocation biomarkers over 12 weeks among individual
participants. Legend: Arrows represent the directional change in pairs of
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